The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

James D Chalmers; Philipp Badorrek; Claudia Diefenbach; Harald Kögler; Wiebke Sauter; Stefan Kreideweiss; Jens M Hohlfeld

doi:10.1183/23120541.00725-2023

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

ERJ Open Res. 2024 Mar 25;10(2):00725-2023. doi: 10.1183/23120541.00725-2023. eCollection 2024 Mar.

Authors

James D Chalmers¹, Philipp Badorrek², Claudia Diefenbach³, Harald Kögler⁴, Wiebke Sauter³, Stefan Kreideweiss³, Jens M Hohlfeld^{2

5

6}

Affiliations

¹ Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
² Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
³ Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
⁴ Boehringer Ingelheim International GmbH, Ingelheim, Germany.
⁵ Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
⁶ German Centre for Lung Research (DZL), Hannover, Germany.

Abstract

Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.